Francis J. Crosson

Nov 20, 2023 | jamanetwork.com | Francis J. Crosson |Aaron S. Kesselheim

Why Some Patients Overpay for Specialty Generic Drugs One key quid pro quo of the US pharmaceutical market is that consumers should expect to pay high prices for a set period of time for drugs offering important clinical advantages, after which generic competition quickly lowers prices closer to the cost of production.

Nov 20, 2023 | jamanetwork.com | Stacie B. Dusetzina |Francis J. Crosson |Aaron S. Kesselheim

Medicare Part D Payments for Generic Imatinib From 2017 to 2023 Imatinib is among the most effective cancer drugs ever developed.1 At US Food and Drug Administration (FDA) approval in 2003, imatinib was the most expensive medication available. This high launch price and price increases have contributed to low patient adherence to therapy,2 making entry of generic versions eagerly anticipated.